According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- RP-A501 was less effective than defendants had led investors to believe;
- to increase its effectiveness, Rocket Pharmaceuticals amended RP-A501’s clinical trial protocol by introducing a novel immunomodulatory agent;
- the foregoing increased the risk that patients would suffer from a Serious Adverse Event (“SAE”);
- accordingly, RP-A501’s safety, as well as its clinical, regulatory, and commercial prospects, were overstated; and
- as a result, defendants’ public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
